Evidence map›Paper›PMID 26553922›Full record

ReviewThe British journal of ophthalmology2016

Current therapeutic developments in atrophic age-related macular degeneration.

Jakub Hanus, Fangkun Zhao, Shusheng Wang

Erratum issuedOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The British journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Protective Effect ofAntioxidants (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Inhibition of GABANeural regeneration research · 2021
    Article
  17. Article
  18. Review
  19. Article
  20. Retinal stem cell transplantation: Balancing safety and potential.Progress in retinal and eye research · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jakub HanusDepartment of Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, USA.
Fangkun ZhaoDepartment of Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, USA Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
Shusheng WangDepartment of Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, USA Department of Ophthalmology, Tulane University, New Orleans, Louisiana, USA.
Tulane University · USFourth Affiliated Hospital of China Medical University · CN

Funding

Regulation of Ocular Angiogenesis by microRNAsR01EY021862 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, SHUSHENG · 2011 to 2021
$2.8M
NEI NIH HHS EY021862NEI NIH HHS R01 EY021862
6 · The paper itself

Abstract

Age-related macular degeneration (AMD), a degenerative disorder of the central retina, is the leading cause of irreversible blindness in the elderly. The underlying mechanism of the advanced form of dry AMD, also named geographic atrophy (GA) or atrophic AMD, remains unclear. Consequently, no cure is available for dry AMD or GA. The only prevention option currently available is the Age-Related Eye Disease Study (AREDS) formulation, which has been demonstrated to slow down the progression of dry AMD. This review summarises recent advances in therapy for dry AMD and GA. Building on the new understanding of the disease and recent technological breakthroughs, numerous ongoing clinical trials have the goal of meeting the need to cure AMD. Therapeutic agents are being developed to target the key features of the disease, including inhibiting the complement pathway and other inflammatory pathways, reducing oxidative stress and protecting retinal pigment epithelial (RPE) cells, inhibiting lipofuscin and visual cycle, regenerating RPE cells from stem cells and restoring choroidal blood flow. Some of these therapeutic options, especially the stem cell-based therapy, hold great promise, which brings great hope for this devastating blinding disease.

Indexed as

Anti-Inflammatory AgentsAntioxidantsGeographic AtrophyHumansImmunotherapyStem Cell TransplantationAnti-Inflammatory AgentsAntioxidantsDegenerationInflammationMaculaRetina

Identifiers

PMID26553922
PMCPMC4944382
OpenAlexW2206819156

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.